Use of Ointments in Prevention of Catheter Related Infections in PD

Condition(s) targeted: Peritoneal Dialysis

Intervention: Mupirocin ointment (Drug); Polysporin Triple (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: University Health Network, Toronto

Official(s) and/or principal investigator(s):
Vanita Jassal, MD, Principal Investigator, Affiliation: University Health Network, Toronto

Overall contact:
Vanita Jassal, MD, Phone: 416 340 3196, Email: vanita.jassal@uhn.on.ca

Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common complication is bacterial infection or ‘peritonitis’. Peritonitis causes severe acute abdominal pain and may lead to failure of peritoneal dialysis treatment, hospitalization or death, particularly if left untreated. Amongst the strategies used to prevent peritonitis, patients are instructed on the regular use of a prophylactic ointment around the point where the catheter exits from the body. At the present time most centers in Canada routinely prescribe mupirocin ointment for use at the exit site, however newer ointments have become available. One such ointment is Polysporin Triple. The aim of this study is to determine if catheter related infections can be significantly reduced by the routine application of Polysporin Triple in comparison to mupirocin ointment. A multi-centre, randomized, double blind, controlled study is proposed. Participants will be randomized to either mupirocin or Polysporin Triple and followed for 18 months or until the first catheter related infection, death or catheter removal. The difference in catheter related infection rates will be compared between the two groups. We anticipate the results of this study will allow clinicians to prescribe the ointment most likely to reduce infections. By doing so this will reduce the complication rate associated with peritoneal dialysis and, ultimately improve survival.

Official title: A Randomized Controlled Double Blind Study Using Mupirocin Versus Polysporin Triple for the Prevention of Catheter-Related Infections in Patients Treated With Peritoneal Dialysis

Study design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study

Primary outcome:

The primary endpoint is the time to first catheter related infection.

This infection will be a composite endpoint that includes one or more of the following PD catheter-related infections a) exit site infection, b) tunnel infection, and c) PD peritonitis.

Secondary outcome:

Removal of the catheter to prevent or halt progression of a catheter related infection

Hospitalizations related to catheter related infection

Death due to catheter-related infection

All-cause mortality

Technique failure (i.e. transfer to hemodialysis)

Mupirocin or Polysporin Triple resistance

Detailed description: Peritoneal dialysis (PD) is used for the treatment of end-stage renal disease in approximately 25% of patients requiring dialysis in Canada. The most common PD related complication is infective peritonitis, a syndrome of acute pain, cloudy peritoneal dialysate, and infection. Although many cases of peritonitis can be treated as an outpatient, recurrent or unresolving infections can result in fibrotic changes in the peritoneal membrane, catheter removal or patient death. Gram positive organisms are amongst the commonest causes of PD peritonitis; however, recent trends show an increasing rate of gram negative and fungal infections. Strategies to prevent peritonitis include the use of prophylactic topical mupirocin at the site where the PD catheter exits from the abdominal wall. Despite this and other innovations peritonitis is still diagnosed, on average, in one patient out of every 24 patients followed for a month. The aim of this study is to determine if the incidence of catheter related infections (exit site infection, tunnel infection or peritonitis) is significantly reduced by the routine application of Polysporin Triple in comparison to mupirocin ointment. A multi-centre randomized double blind, controlled study is proposed. Polysporin Triple will be compared against the current standard of care. All patients currently being treated with, or starting onto, peritoneal dialysis will be eligible. Participants will be randomized to one of two treatment arms (mupirocin; Polysporin Triple) and stratified according to a) centre b) vintage (incident versus prevalent), and c) type of PD (chronic ambulatory peritoneal dialysis vs. automated PD). Patients will be followed for 18 months or until the first catheter related infection, death or catheter removal due to technique failure. Catheter related infections will be strictly defined using current guidelines and categorized into exit site infections, infective peritonitis or tunnel infections.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Able and willing to provide informed consent*

2. Age over 18 years

3. Has a peritoneal dialysis catheter in situ and

- Is established on PD for more than 3 months (prevalent patients)

- Is undergoing training for or has initiated PD within the last 3 months (incident

patients)

4. Medically stable (as defined by primary nephrologist)

5. Regularly applying mupirocin ointment to catheter exit site

Exclusion Criteria:

1. Presence of acute renal failure

2. Catheter related infection at the time of recruitment or within the previous 3 months

3. Use of an oral or IV antibiotic at the time of randomization or within the previous 1 week.

4. Known allergy to any component of gentamicin or mupirocin

Vanita Jassal, MD, Phone: 416 340 3196, Email: vanita.jassal@uhn.on.ca

University Health Network, Toronto, Ontario M5G 2C4, Canada; Recruiting
Vanita Jassal, MD, Phone: 416 340 3196, Email: vanita.jassal@uhn.on.ca
Debra Gordon, RN, Phone: (416) 340-4800, Ext: 6362, Email: debra.gordon@uhn.on.ca
Vanita Jassal, MD, Principal Investigator

Scarborough General Hospital, Toronto, Ontario M1P 2V5, Canada; Recruiting
Janet Roscoe, MD, Phone: (416) 438-9000, Email: jroscoe@on.aibn.com
Fred Chan, RN, Phone: (416) 431-8183, Email: fredchan@rogers.com
Janet Roscoe, MD, Principal Investigator

Starting date: February 2006
Ending date: August 2008
Last updated: November 16, 2006